Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review.

Guillain-Barré syndrome (GBS) resulting from the use of immune checkpoint inhibitors (ICIs) is relatively uncommon but has been reported. Herein, we discuss a case of a 67-year-old patient who received neoadjuvant ICI for treatment of non-small cell lung cancer and then presented with lower extremity weakness and areflexia, progressing to respiratory muscle and upper extremity weakness. Given the increasing use of ICI in cancer management, awareness of neurological autoimmune side effects is essential. ICI-mediated GBS can be severe and fatal if not diagnosed promptly. We discuss a case of ICI-induced GBS and review literature on current management approaches.

Hemorrhagic Chemosis Associated With Isatuximab Use in an Elderly Lady With Multiple Myeloma.

Isatuximab is a newly approved targeted therapy for the treatment of patients with advanced multiple myeloma. Infusion reactions happen often with targeted therapies like isatuximab and can be severe or even life-threatening. However, ocular infusion reactions are rare. We report a 75-year-old female who presented with right eye erythema and associated pain and was found to have had a rapid onset of unilateral hemorrhagic chemosis following an initial infusion of isatuximab. She developed erythema in her right eye, associated with pain, swelling, burning, and a foreign body sensation. Visual acuity in the right eye decreased to light perception only within the first few minutes. The infusion was discontinued, and the patient was treated with steroids and intraocular pressure-lowering drugs. She was monitored for 24 hours and then discharged after symptomatic improvement.

Newly Diagnosed Idiopathic Thrombocytopenia Post COVID-19 Vaccine Administration.

A few individuals are believed to have developed immune thrombocytopenia (ITP) following the administration of the coronavirus disease 2019 (COVID-19) vaccine. This phenomenon has been reported in a few case reports and also in some recent news articles. In this report, we discuss a case of a 54-year-old Caucasian female who presented to the emergency room with life-threatening thrombocytopenia in the setting of de novo ITP following COVID-19 vaccine administration. Due to the relapsing nature of ITP, it is unclear if the patient has achieved complete remission of the disease.